QIAGEN powered by

Webinars and events

Loading Events

« All Events

  • This event has passed.

Drug treatment, toxicology and target safety assessment using QIAGEN IPA and OmicSoft

May 29, 2022 @ 1:00 am - 2:30 pm

In this 90-minute training, you’ll learn how to do drug treatment, toxicology and target safety assessment-related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands.
Using public data from GTEx (normal tissue), GEO, cancer collections and more, you’ll learn how to use Omicsoft Lands to:
• Investigate a drug target or biomarker expression across different normal tissues, disease conditions, treatments and more
• Correlate expression of two or more genes
• Identify a list of genes or biomarkers specific to treatment, disease, normal tissue, cell type and more

Using findings from peer-reviewed publications and other sources, attendees we’ll explore with you how to use QIAGEN IPA to:
• Study the impact of targeting a gene/protein on different toxicological and biological functions
• Derive tox findings for a gene of interest from QIAGEN IPA’s knowledgebase
• Identify and study toxicity-related pathways, regulators and functions for an internal dataset or a public dataset
• Compare different drug treatments, other conditions or multi-omics data for novel discoveries

Click here to register.


Date: May 29, 2022
 1:00 am - 2:30 pm
Register for event
Event Categories:


Virtual – Americas – EST
United States + Google Map
Register for event

On-demand Webinars

  • Supercharge your AI in drug discovery with high-quality biomedical data

    If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn’t enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights, the underlying data must be of ‘hig...

  • Scale up NGS bioinformatics analysis throughput with QIAGEN CLC Genomics cloud computing

    Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. ...

  • QIAGEN Biomedical Knowledge Base: Data- and analytics-driven drug discovery

    Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this one-hour training, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle appli...

  • Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness

    Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions, and provide prognostic information. However, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic vari...

  • A breakthrough for rare disease: Completing the Clinical exome gap!

    In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now, with the addition of AI-derived literature references for rare disease genes, QCI Interpret provides complete exome coverage, on top of the existing unrivalled man...

  • What’s new in QIAGEN IPA Fall Release 2023?

    Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics, amongst others, will be • Newly added findings and pathways • Reactome pathways • Artificial intelligence approves to pathways ...